Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 4,780 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Cancers Clear all

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions: ABI-1968; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 27 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: CC-122, CC-223, Rituximab, CC-292; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 8
States / cities: Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more

Conditions: Multiple Myeloma
Interventions: Darinaparson; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Glendale, Arizona • Santa Barbara, California • Santa Rosa, California + 5 more

Conditions: Multiple Myeloma
Interventions: First-line therapy, Second-line Multiple Myeloma treatments; Other · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 3,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 252
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more

Conditions: Human Papillomavirus, Human Immunodeficiency Virus, Hepatitis C, ColoRectal Cancer
Interventions: OraQuick Swab, Fecal Immunochemical Test, OraQuick Fingerstick, Standard Screening Tests, HPV Self-Sampling Test, Home Based Screening Tests; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 50 Years to 64 Years
Enrollment: 754 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Neoplasm
Interventions: Isatuximab SAR650984, Atezolizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Santa Monica, California • Boston, Massachusetts • Houston, Texas

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: MILs, Melphalan, PCV13; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Interventions: WTX-330; Drug
Lead sponsor: Werewolf Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 9
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Breast Cancer
Interventions: Indole-3-carbinol, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hepatobiliary Cancers
Interventions: Durvalumab-based combination therapies in observational study setting, Non Durvalumab-based therapies in observational study setting, Durvalumab-based combination therapies in observational study settings; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more

Conditions: Lymphedema, Lymphedema of Upper Arm, Lymphedema, Breast Cancer
Interventions: Crossover Device (PCD or Dayspring - alternate to first group); Device
Lead sponsor: Koya Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Los Altos, California • Morgan Hill, California

Conditions: Breast Cancer
Interventions: Blood collection for GDF-15; Other
Lead sponsor: Breast Cancer Trials, Australia and New Zealand; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Multiple Myeloma
Interventions: Elranatamab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 17
States / cities: Irvine, California • Orange, California • Fort Collins, Colorado + 9 more

Conditions: Cancer
Interventions: Paclitaxel, 5-Fluorouracil (5FU), Carboplatin, Leucovorin, Irinotecan, BMS-906024; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Interventions: atumelnant; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fever, Neutropenia
Interventions: Low Risk: Oupatient Management, Low Risk: Inpatient Management, High Risk: Inpatient Management; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 0 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: rituximab, lenalidomide, microarray analysis, flow cytometry, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Talquetamab, Daratumumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Sirolimus, PEG-asparaginase; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Sotatercept, Placebo; Drug
Lead sponsor: Rebecca Silbermann; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Myeloid Leukemia
Interventions: AZD1152; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Doxil; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: arsenic trioxide, tretinoin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 15 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Connect® MM- The Multiple Myeloma Disease Registry

Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer

Observational Study Protocol: LIVER-R

A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of the Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema

GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Fever and Neutropenia in Pediatric Oncology Patients

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy